COMP <GO>
COR vs LLY // EV/EBITDA & P/E VALUATION
Cencora Inc. (NYSE) VS. Eli Lilly and Company (NYSE) • 15-METRIC TALLY: COR 5
— LLY 10
▲ EV/EBITDA & P/E VALUATION LEADER: COR
LAST: $330.84 (+0.09%) • MKT CAP: $63.07B
valuation
21.6x
LAST: $1,417.54 (+3.19%) • MKT CAP: $1.33T
valuation
36.4x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (COR VS. LLY)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | COR | LLY | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 3.60% | 83.64% | -80.04 | LLY | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 26.80% | 32.36% | -5.56 | LLY | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | 21.6x | 36.4x | -14.82 | COR | /valuation <GO> |
| Free Cash Flow Yield | 5.08% | 2.30% | +2.78 | COR | /fcf-yield <GO> |
| Operating Margin | 0.80% | 40.21% | -39.41 | LLY | /operating-margins <GO> |
| Net Profit Margin | 0.50% | 31.90% | -31.40 | LLY | /net-margins <GO> |
| Revenue Growth (YoY) | 9.30% | 45.51% | -36.21 | LLY | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.69% | 0.49% | +0.20 | COR | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 5.27 | 9.29 | -4.02 | LLY | /balance-sheet <GO> |
| Piotroski F-Score Quality | 6/9 | 9/9 | -3.00 | LLY | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 6.50% | 6.77% | -0.27 | COR | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 54.1 | 77.9 | -23.74 | LLY | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 0.88 | 0.51 | +0.37 | COR | /macro-sensitivity <GO> |
| Forward P/E Multiple | 37.8x | 26.3x | +11.55 | LLY | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $63.07B | $1.33T | -$1.27T | LLY | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | COR REV | LLY REV | COR GROSS % | LLY GROSS % | COR FCF | LLY FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $321.33B | $65.18B | 3.6% | 83.0% | $3.21B | $16.81B |
| FY 2024 | $293.96B | $45.04B | 3.4% | 81.3% | $3.00B | $8.82B |
| FY 2023 | $262.17B | $34.12B | 44.0% | 79.3% | -$7.89B | $4.24B |
| FY 2022 | — | $28.54B | — | 76.8% | — | $7.59B |
| FY 2021 | — | $28.32B | — | 74.2% | — | $7.37B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
COR // BETA 0.88
LLY // BETA 0.51